倾向评分匹配回顾性队列研究:新冠第一波疫情期间降钙素原检测对住院患者抗生素使用的影响
多中心回顾性观察性队列研究分析英格兰和威尔士5960例新冠住院患者,1548例(26.0%)基线接受降钙素原检测。倾向评分匹配后,基线降钙素原检测与早期抗生素处方平均减少0.43天(95%CI 0.22-0.64天,P<0.001)及总抗生素处方减少0.72天(95%CI 0.06-1.38天,P=0.03)相关,未增加死亡率、住院/ICU时长或耐药菌继发感染率。
要点
- 基线降钙素原检测与早期抗生素处方平均减少0.43天相关(95%CI 0.22-0.64天,P<0.001)。
- 基线降钙素原检测与总抗生素处方平均减少0.72天相关(95%CI 0.06-1.38天,P=0.03)。
- 基线降钙素原检测未增加死亡率、住院/ICU时长或耐药菌继发感染率。
核心结论
- 基线降钙素原检测在大流行早期似乎是有效的抗菌药物管理工具:减少抗生素处方且无伤害证据。
- 研究强调需要在国家卫生服务体系中对感染诊断工具进行嵌入式快速评估,以便即使在困难情况下引入临床实践也有临床效用证据支持。
研究设计与样本
- 多中心、回顾性、观察性队列研究,使用英格兰/威尔士急性医院信托/卫生委员会的个体临床数据。
- 纳入标准:年龄≥16岁,入住参与信托/卫生委员会,且在2020年2月1日至2020年6月30日间确诊新冠阳性。
- 共分析5960例患者数据:1548例(26.0%)有基线降钙素原检测,4412例(74.0%)无。
- 使用倾向评分匹配分析。
- 研究注册号:ISRCTN66682918。
主要发现
- 倾向评分匹配后,基线降钙素原检测与早期抗生素处方平均减少0.43天相关(95%CI 0.22-0.64天,P<0.001)。
- 基线降钙素原检测与总抗生素处方平均减少0.72天相关(95%CI 0.06-1.38天,P=0.03)。
- 基线降钙素原检测与死亡率增加、住院/ICU时长增加或耐药菌继发感染率增加无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Procalcitonin (PCT) is a blood marker used to help diagnose bacterial infections and guide antibiotic treatment. PCT testing was widely used/adopted during the COVID-19 pandemic in the UK. OBJECTIVES: Primary: to measure the difference in length of early (during first 7 days) antibiotic prescribing between patients with COVID-19 who did/did not have baseline PCT testing during the first wave of the pandemic. Secondary: to measure differences in length of hospital/ICU stay, mortality, total days of antibiotic prescribing and resistant bacterial infections between these groups. METHODS: Multi-centre, retrospective, observational, cohort study using patient-level clinical data from acute hospital Trusts/Health Boards in England/Wales. Inclusion: patients ≥16 years, admitted to participating Trusts/Health Boards and with a confirmed positive COVID-19 test between 1 February 2020 and 30 June 2020. RESULTS: Data from 5960 patients were analysed: 1548 (26.0%) had a baseline PCT test and 4412 (74.0%) did not. Using propensity-score matching, baseline PCT testing was associated with an average reduction in early antibiotic prescribing of 0.43 days [95% confidence interval (CI): 0.22-0.64 days, P < 0.001) and of 0.72 days (95% CI: 0.06-1.38 days, P = 0.03] in total antibiotic prescribing. Baseline PCT testing was not associated with increased mortality or hospital/ICU length of stay or with the rate of antimicrobial-resistant secondary bacterial infections. CONCLUSIONS: Baseline PCT testing appears to have been an effective antimicrobial stewardship tool early in the pandemic: it reduced antibiotic prescribing without evidence of harm. Our study highlights the need for embedded, rapid evaluations of infection diagnostics in the National Health Service so that even in challenging circumstances, introduction into clinical practice is supported by evidence for clinical utility. STUDY REGISTRATION NUMBER: ISRCTN66682918.
引用
- Sandoe JAT, Grozeva D, Albur M, et al. A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. J Antimicrob Chemother. 2024. PMID: 39248146. doi:10.1093/jac/dkae246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。